We are proud to launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life.

BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs.

"We are excited to introduce BioGaia® Gastrus® PURE ACTION to the market - a product that exemplifies our dedication to delivering innovative, science-backed solutions for gut health. Designed with consumer needs in mind, this product aims to enhance the quality of life for individuals with sensitive digestive systems. Statistics show that many consumers discover probiotics, and BioGaia, while seeking relief from gut discomfort, which is why we believe this product will meet a significant need and further strengthen our position as a trusted leader in the field of probiotics", said Linda Hägglund, Chief Marketing Officer.
 

What is FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols)?

These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders.

Product availability:

Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies.

Supported by clinical research:

The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of your digestive system, ensuring they reach your gut alive.

The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria.

Participants who used the product demonstrated:

Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief.

Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo.

Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation.

Study References: 

Cruchet, et al. Front Gastroenterol. 2024;2:1296048. doi:10.3389/fgstr.2023.1296048. 

König, et al. PLOS ONE. 2024;19(11):e0312464. doi:10.1371/journal.pone.0312464

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Mikaela Idermark Stern, Corporate Communications
Email: mikaela.idermark.stern@biogaia.com
Phone: +46 730 95 61 50

About BioGaia
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com